Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
Carolina Marin Comini, Ana Carolina
de Sousa, Isadora Martins
Abrahao Reis, Pedro Cotta
Carvalho, Bruno Murad
Guedes Camandaroba, Marcos Pedro
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
[2] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[3] Fac Med Barbacena FAME FUNJOB, Lavras, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16132
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis
    Li, Danni
    Li, Jingyi
    Liu, Yunpeng
    Qu, Xiujuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis
    Peng, Wei
    Pan, Yangxun
    Xie, Lan
    Yang, Zhoutian
    Ye, Zhiwei
    Chen, Jinbin
    Wang, Juncheng
    Hu, Dandan
    Xu, Li
    Zhou, Zhongguo
    Chen, Minshan
    Fang, Aiping
    Zhang, Yaojun
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [33] A SYSTEMATIC LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE III RANDOMIZED CONTROLLED TRIALS OF HEPATOCELLULAR CARCINOMA IN A FIRST-LINE SETTING
    Attri, S.
    Singh, B.
    VALUE IN HEALTH, 2023, 26 (06) : S35 - S35
  • [34] Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis
    Vogel, Arndt
    Finn, Richard S.
    Zumofen, Marie-Helene Blanchet
    Heuser, Carolina
    Alvarez, Javier Sanchez
    Leibfried, Michael
    Mitchell, Catherine R.
    Batson, Sarah
    Redhead, Gabrielle
    Gaillard, Vincent E.
    Kudo, Masatoshi
    LIVER CANCER, 2023, 12 (06) : 510 - 520
  • [35] First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis
    Shpilsky, Jason
    Catalano, Paul J.
    McDermott, David F.
    KIDNEY CANCER, 2021, 5 (03) : 153 - 163
  • [36] The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
    Lee, Shou-Wu
    Yang, Sheng-Shun
    Lien, Han-Chung
    Peng, Yen-Chun
    Tung, Chun-Fang
    Lee, Teng-Yu
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [37] The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials
    Vitale, Elsa
    Rizzo, Alessandro
    Maistrello, Lorenza
    Nardulli, Patrizia
    Talienti, Tiziana
    Quaresmini, Davide
    De Summa, Simona
    Massafra, Raffaella
    Silvestris, Nicola
    Brunetti, Oronzo
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] COMPARISON OF FIRSTLINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Hur, Moon Haeng
    Park, Youngsu
    Ko, Yunmi
    Shin, Hyunjae
    Park, Jeayeon
    Kim, Ju Yeon
    Lee, Yun Bin
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Jeong-Hoon
    HEPATOLOGY, 2023, 78 : S1821 - S1821
  • [39] Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Tun, Aung Myint
    Thein, Kyaw Zin
    LinThein, Wai
    Guevara, Elizabeth
    FUTURE SCIENCE OA, 2019, 5 (09):
  • [40] First-line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
    Fong, Khi Yung
    Zhao, Joseph Jonathan
    Sultana, Rehena
    Lee, Joycelyn Jie Xin
    Lee, Suat Ying
    Chan, Stephen Lam
    Yau, Thomas
    Tai, David Wai Meng
    Sundar, Raghav
    Too, Chow Wei
    LIVER CANCER, 2023, 12 (01) : 7 - 18
12345